SpyBiotech Limited news
Oxford, UK, 16 November 2021: SpyBiotech, a biotechnology company with a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, today announces the appointment of Simon Jones as VP of Finance and Operations, and the expansion of its scientific team with four new hires.
Simon takes up the permanent position of VP Finance and Operations from Vien Phan, who held the role of Interim Finance Director, steering
SpyBiotech has today been featured in The Guardian’s Value of Vaccines supplement, discussing the technological solutions we have developed to accelerate vaccine generation for COVID-19 variants and potentially a range of other diseases for which there are no approved treatments.
"The COVID-19 vaccine uses SpyBiotech`s unique protein "superglue" technology to display the SARS Cov-2 spike protein receptor binding domain on the surface of
SpyBiotech announces the appointments of Dan Menichella as Non-Executive Director and Dr Norman Begg as Scientific Advisor
Oxford, U.K., March 8, 2021: SpyBiotech, a British biotechnology company with a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, today announces the appointments of Dan Menichella as an independent, non-executive director and Norman Begg as a scientific advisor.
Mr Menichella brings with him over 20
SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman to support its novel vaccine platform through accelerated clinical development
- SpyBiotech has raised $32.5M from leading investors to advance development of its novel “plug and display” vaccine platform technology
- Braavos Investment Advisers led the round, joined by new investor Oxford Investment Consultants; founding investors Oxford Sciences Innovation and G
A study from Scripps using SpyTag/SpyCatcher technology shows that the receptor-binding domain and stabilized SARS-CoV-2 spike displayed on ferritin nanoparticles as vaccine antigens, elicited potent immune responses.